Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension
Autor: | Margrethe Friberg, Lene Poulsen, Ivan Noer, Lars Romer Krusell, Ole Lederballe Pedersen |
---|---|
Rok vydání: | 1989 |
Předmět: |
Adult
Male Drug medicine.medical_specialty Supine position media_common.quotation_subject Urology Blood Pressure Pharmacology law.invention Amiloride Hydrochlorothiazide Double-Blind Method Randomized controlled trial Heart Rate law Humans Medicine Pharmacology (medical) Serum Albumin Radio-Iodinated Aged media_common business.industry Body Weight Indapamide General Medicine Middle Aged Crossover study Blood pressure Hypertension Potassium Female Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Cardiovascular Drugs and Therapy. 3:141-144 |
ISSN: | 1573-7241 0920-3206 |
DOI: | 10.1007/bf01883857 |
Popis: | In a randomized, double-blind crossover trial, indapamide (IND) 2.5 mg and hydrochlorothiazide 25 mg + amiloride 2.5 mg (HCTZ + A) were found to be equally effective in reducing blood pressure (BP) in 13 patients with moderate to severe hypertension already receiving chronic treatment with a beta blocker and a vasodilatator (supine BP during run-in: 169/103 +/- 21/5 mmHg; on IND: 149/91 +/- 21/14 mmHg; on HCTZ + A 144/88 +/- 23/5 mmHg). Both drugs induced insignificant reductions in body weight, and no change in plasma volume was seen. Serum potassium was significantly reduced on both regimens--the values recorded on IND being significantly lower than those seen on HCTZ + A. Values below 3.0 mmol/l were found in two patients receiving IND, but no subjective side effects were reported. Hyperuricemia occurred with the same frequency on both regimens. It is concluded that IND, just like the thiazide diuretics, is useful as the third drug in patients needing triple drug therapy to control BP, but metabolic adverse effects are not avoided by the choice of this drug. |
Databáze: | OpenAIRE |
Externí odkaz: |